Moderna's COVID vaccine booster gets EMA nod for use in kids over 6
Maddie Meyer/Getty Images News                 
A panel of the European Medicines Agency (EMA) recommended the expanded approval ofÂ Moderna's (NASDAQ:MRNA)Â Spikevax bivalent Original/Omicron BA.4-5 COVID-19 vaccine for use as a booster in children aged six to 11 years.
The vaccine is already approved forÂ individuals 12 years of age and older.
The European Commission (EC) will now make a decision on the change to the marketing authorization of the vaccine.